Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

508 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Phase II, randomized trial of preoperative epirubicin-paclitaxel +/- gefitinib with biomarker evaluation in operable breast cancer.
Guarneri V, Frassoldati A, Ficarra G, Puglisi F, Andreetta C, Michelotti A, Cresti N, Boni C, Bisagni G, Berardi R, Battelli N, Santoro A, Banna G, Bottini A, Di Blasio B, Maiorana A, Piacentini F, Giovannelli S, Jovic G, Conte P. Guarneri V, et al. Among authors: maiorana a. Breast Cancer Res Treat. 2008 Jul;110(1):127-34. doi: 10.1007/s10549-007-9688-3. Epub 2007 Aug 9. Breast Cancer Res Treat. 2008. PMID: 17687648 Free article. Clinical Trial.
Double-blind, placebo-controlled, multicenter, randomized, phase IIb neoadjuvant study of letrozole-lapatinib in postmenopausal hormone receptor-positive, human epidermal growth factor receptor 2-negative, operable breast cancer.
Guarneri V, Generali DG, Frassoldati A, Artioli F, Boni C, Cavanna L, Tagliafico E, Maiorana A, Bottini A, Cagossi K, Bisagni G, Piacentini F, Ficarra G, Bettelli S, Roncaglia E, Nuzzo S, Swaby R, Ellis C, Holford C, Conte P. Guarneri V, et al. Among authors: maiorana a. J Clin Oncol. 2014 Apr 1;32(10):1050-7. doi: 10.1200/JCO.2013.51.4737. Epub 2014 Mar 3. J Clin Oncol. 2014. PMID: 24590635 Free article. Clinical Trial.
Prospective Biomarker Analysis of the Randomized CHER-LOB Study Evaluating the Dual Anti-HER2 Treatment With Trastuzumab and Lapatinib Plus Chemotherapy as Neoadjuvant Therapy for HER2-Positive Breast Cancer.
Guarneri V, Dieci MV, Frassoldati A, Maiorana A, Ficarra G, Bettelli S, Tagliafico E, Bicciato S, Generali DG, Cagossi K, Bisagni G, Sarti S, Musolino A, Ellis C, Crescenzo R, Conte P. Guarneri V, et al. Among authors: maiorana a. Oncologist. 2015 Sep;20(9):1001-10. doi: 10.1634/theoncologist.2015-0138. Epub 2015 Aug 5. Oncologist. 2015. PMID: 26245675 Free PMC article. Clinical Trial.
Clinical and molecular predictors of long-term response in HER2 positive metastatic breast cancer patients.
Omarini C, Bettelli S, Caprera C, Manfredini S, Caggia F, Guaitoli G, Moscetti L, Toss A, Cortesi L, Kaleci S, Maiorana A, Cascinu S, Conte PF, Piacentini F. Omarini C, et al. Among authors: maiorana a. Cancer Biol Ther. 2018;19(10):879-886. doi: 10.1080/15384047.2018.1480287. Epub 2018 Aug 1. Cancer Biol Ther. 2018. PMID: 30067438 Free PMC article.
Mutational Profile of Metastatic Breast Cancer Tissue in Patients Treated with Exemestane Plus Everolimus.
Omarini C, Filieri ME, Bettelli S, Manfredini S, Kaleci S, Caprera C, Nasso C, Barbolini M, Guaitoli G, Moscetti L, Maiorana A, Conte PF, Cascinu S, Piacentini F. Omarini C, et al. Among authors: maiorana a. Biomed Res Int. 2018 Jul 24;2018:3756981. doi: 10.1155/2018/3756981. eCollection 2018. Biomed Res Int. 2018. PMID: 30140695 Free PMC article.
508 results